AdaptHealth Corp. (AHCO) Form 10-Q — Aug 4, 2026
AdaptHealth reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, powered by organic growth and a sharp ramp in at-risk capitated revenue to $103.3 million from $31.1 million a year earlier. The company services roughly 4.8 million patients annually across ~670 locations. Despite the top-line strength, the company swung to a net loss attributable of $133.9 million, or $(0.99) per share, versus net income of $14.7 million ($0.10) in Q2 2025, after recognizing $144.2 million of non-cash goodwill impairment charges in its Respiratory Health and Wellness at Home reporting units.
Key figures
- Revenue
- 740307000
- Revenue Yoy
- 12.7% (Q2 2026 vs Q2 2025)
- Total Assets
- 4340869000
- Cash Position
- 43289000
- Shares Outstanding
- 136344196
- Six month revenue
- $1,420.2 million vs $1,301.6 million prior year
- Restructuring cost
- ~$7.0 million with ~$26.8 million expected annual savings
- Goodwill impairment
- $144.2 million (Respiratory Health $79.1M, Wellness at Home $65.1M)
- Capitated revenue q2
- $103.3 million vs $31.1 million in Q2 2025
- Litigation settlement
- $14.5 million (North Carolina class action)
- Delayed draw term loan
- $325.0 million borrowed July 27, 2026 to redeem 6.125% Senior Notes
- Acquisitions six months
- $127.3 million cash for capitated-contract transitions
- Adjusted ebitda q2 2026
- $132.0 million vs $136.4 million in Q2 2025
- Diabetes health sale price
- $235.0 million cash, expected close Q1 2027
- Operating cash flow six months
- $239.0 million
Price after filing
Close on the filing date to close N calendar days later (from $10.68). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.